{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:55:20Z","timestamp":1791456920434,"version":"4.3.4"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03382-6","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:34:49Z","timestamp":1760178889000},"page":"5879-5895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Advances in Hereditary Angioedema: A Focus on Present and Future Options"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6357-6010","authenticated-orcid":false,"given":"Kelsey","family":"Uminski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"3382_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1808012","volume":"382","author":"PJ Busse","year":"2020","unstructured":"Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382:1136\u201348.","journal-title":"N Engl J Med"},{"key":"3382_CR2","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jaci.2013.03.034","volume":"131","author":"BL Zuraw","year":"2013","unstructured":"Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor\u2013associated angioedema. J Allergy Clin Immunol. 2013;131:1491-1493.e25.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR3","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.2500\/aap.2020.41.200065","volume":"41","author":"V Azmy","year":"2020","unstructured":"Azmy V, Brooks JP, Hsu FI. Clinical presentation of hereditary angioedema. Allergy Asthma Proc. 2020;41:S18-21.","journal-title":"Allergy Asthma Proc"},{"key":"3382_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaci.2022.11.027","volume":"151","author":"Z Ren","year":"2023","unstructured":"Ren Z, Zhao S, Li T, Wedner HJ, Atkinson JP. Insights into the pathogenesis of hereditary angioedema using genetic sequencing and recombinant protein expression analyses. J Allergy Clin Immunol. 2023;151:1040-1049.e5.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1172\/JCI98869","volume":"129","author":"D Haslund","year":"2018","unstructured":"Haslund D, Ry\u00f8 LB, Seidelin Majidi S, et al. Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema. J Clin Invest. 2018;129:388\u2013405.","journal-title":"J Clin Invest"},{"key":"3382_CR6","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaci.2023.04.023","volume":"152","author":"LB Ry\u00f8","year":"2023","unstructured":"Ry\u00f8 LB, Haslund D, Rovsing AB, et al. Restriction of C1-inhibitor activity in hereditary angioedema by dominant-negative effects of disease-associated SERPING1 gene variants. J Allergy Clin Immunol. 2023;152:1218-1236.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.alit.2023.04.004","volume":"72","author":"T Miyata","year":"2023","unstructured":"Miyata T, Horiuchi T. Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency. Allergol Int. 2023;72:375\u201384.","journal-title":"Allergol Int"},{"key":"3382_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1055\/s-0042-1758820","volume":"50","author":"RS Petersen","year":"2024","unstructured":"Petersen RS, Fijen LM, Levi M, Cohn DM. Hereditary angioedema: the clinical picture of excessive contact activation. Semin Thromb Hemost. 2024;50:978\u201388.","journal-title":"Semin Thromb Hemost"},{"key":"3382_CR9","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2500\/aap.2020.41.200081","volume":"41","author":"HJ Wedner","year":"2020","unstructured":"Wedner HJ. Hereditary angioedema: pathophysiology (HAE type\u00a0I, HAE type\u00a0II, and HAE nC1-INH). Allergy Asthma Proc. 2020;41:S14\u20137.","journal-title":"Allergy Asthma Proc"},{"key":"3382_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jaci.2021.01.011","volume":"148","author":"K Bork","year":"2021","unstructured":"Bork K, Wulff K, M\u00f6hl BS, et al. Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation. J Allergy Clin Immunol. 2021;148:1041\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR11","doi-asserted-by":"publisher","first-page":"1146834","DOI":"10.3389\/fphys.2023.1146834\/full","volume":"14","author":"A Shamanaev","year":"2023","unstructured":"Shamanaev A, Dickeson SK, Ivanov I, et al. Mechanisms involved in hereditary angioedema with normal C1-inhibitor activity. Front Physiol. 2023;14:1146834. https:\/\/doi.org\/10.3389\/fphys.2023.1146834\/full.","journal-title":"Front Physiol"},{"key":"3382_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12016-021-08835-8","volume":"60","author":"J Sharma","year":"2021","unstructured":"Sharma J, Jindal AK, Banday AZ, et al. Pathophysiology of hereditary angioedema (HAE) beyond the SERPING1 gene. Clinic Rev Allerg Immunol. 2021;60:305\u201315.","journal-title":"Clinic Rev Allerg Immunol"},{"key":"3382_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jaci.2024.05.017","volume":"154","author":"M D\u2019Apolito","year":"2024","unstructured":"D\u2019Apolito M, Santacroce R, Vazquez DO, et al. DAB2IP associates with hereditary angioedema: insights into the role of VEGF signaling in HAE pathophysiology. J Allergy Clin Immunol. 2024;154:698\u2013706.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR14","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.jacig.2024.100223","volume":"3","author":"D Vincent","year":"2024","unstructured":"Vincent D, Parsopoulou F, Martin L, et al. Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency. J Allergy Clin Immunol Glob. 2024;3:100223.","journal-title":"J Allergy Clin Immunol Glob"},{"key":"3382_CR15","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1111\/all.14454","volume":"75","author":"A Ariano","year":"2020","unstructured":"Ariano A, D\u2019Apolito M, Bova M, et al. A myoferlin gain-of-function variant associates with a new type of hereditary angioedema. Allergy. 2020;75:2989\u201392.","journal-title":"Allergy"},{"key":"3382_CR16","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/all.13869","volume":"74","author":"K Bork","year":"2019","unstructured":"Bork K, Wulff K, Rossmann H, et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy. 2019;74:2479\u201381.","journal-title":"Allergy"},{"key":"3382_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/all.13270","volume":"73","author":"K Bork","year":"2018","unstructured":"Bork K, Wulff K, Steinm\u00fcller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. 2018;73:442\u201350.","journal-title":"Allergy"},{"key":"3382_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/all.12648","volume":"70","author":"K Bork","year":"2015","unstructured":"Bork K, Wulff K, Witzke G, Hardt J. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy. 2015;70:1004\u201312.","journal-title":"Allergy"},{"key":"3382_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jaci.2017.05.020","volume":"141","author":"V Bafunno","year":"2018","unstructured":"Bafunno V, Firinu D, D\u2019Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. 2018;141:1009\u201317.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR20","doi-asserted-by":"publisher","first-page":"e0265847","DOI":"10.1371\/journal.pone.0265847","volume":"17","author":"M Isono","year":"2022","unstructured":"Isono M, Kokado M, Kato K. Why does it take so long for rare disease patients to get an accurate diagnosis?\u2014A qualitative investigation of patient experiences of hereditary angioedema. PLoS ONE. 2022;17:e0265847.","journal-title":"PLoS ONE"},{"key":"3382_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.anai.2016.08.014","volume":"117","author":"A Zanichelli","year":"2016","unstructured":"Zanichelli A, Longhurst HJ, Maurer M, et al. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Ann Allergy Asthma Immunol. 2016;117:394\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3382_CR22","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S86293","author":"MP Henao","year":"2016","unstructured":"Henao MP, Craig T, Kraschnewski J, Kelbel T. Diagnosis and screening of patients with hereditary angioedema in primary care. Ther Clin Risk Manag. 2016. https:\/\/doi.org\/10.2147\/TCRM.S86293.","journal-title":"Ther Clin Risk Manag"},{"key":"3382_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124:600\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3382_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-021-01717-4","volume":"16","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Murphy R, De La Cruz M, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis. 2021;16:94. https:\/\/doi.org\/10.1186\/s13023-021-01717-4.","journal-title":"Orphanet J Rare Dis"},{"key":"3382_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-024-03265-z","volume":"19","author":"X Guan","year":"2024","unstructured":"Guan X, Sheng Y, Liu S, He M, Chen T, Zhi Y. Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review. Orphanet J Rare Dis. 2024;19:256. https:\/\/doi.org\/10.1186\/s13023-024-03265-z.","journal-title":"Orphanet J Rare Dis"},{"key":"3382_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaci.2016.02.041","volume":"138","author":"ZLM Hofman","year":"2016","unstructured":"Hofman ZLM, Relan A, Zeerleder S, Drouet C, Zuraw B, Hack CE. Angioedema attacks in patients with hereditary angioedema: local manifestations of a systemic activation process. J Allergy Clin Immunol. 2016;138:359\u201366.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR27","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1182\/blood-2018-06-860270","volume":"133","author":"I Ivanov","year":"2019","unstructured":"Ivanov I, Matafonov A, Sun M, et al. A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor\u00a0XII heavy chain. Blood. 2019;133:1152\u201363.","journal-title":"Blood"},{"key":"3382_CR28","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.jaci.2016.02.021","volume":"138","author":"S De Maat","year":"2016","unstructured":"De Maat S, Bj\u00f6rkqvist J, Suffritti C, et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor\u00a0XII mutations. J Allergy Clin Immunol. 2016;138:1414-1423.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.1090732\/full","author":"S Hintze","year":"2023","unstructured":"Hintze S, M\u00f6hl BS, Beyerl J, et al. Mutant plasminogen in hereditary angioedema is bypassing FXII\/kallikrein to generate bradykinin. Front Physiol. 2023. https:\/\/doi.org\/10.3389\/fphys.2022.1090732\/full.","journal-title":"Front Physiol"},{"key":"3382_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02046\/full","author":"C Maas","year":"2019","unstructured":"Maas C. Plasminflammation\u2014an emerging pathway to bradykinin production. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.02046\/full.","journal-title":"Front Immunol"},{"key":"3382_CR31","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.jaci.2021.05.016","volume":"148","author":"M Maurer","year":"2021","unstructured":"Maurer M, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Banerji A, et al. Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. J Allergy Clin Immunol. 2021;148:1526\u201332.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2500\/aap.2013.34.3624","volume":"34","author":"RG Gower","year":"2013","unstructured":"Gower RG. HAE update: determining optimal patient specific therapy. Allergy Asthma Proc. 2013;34:7\u201312.","journal-title":"Allergy Asthma Proc"},{"key":"3382_CR33","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update. Allergy. 2022;77:1961\u201390.","journal-title":"Allergy"},{"key":"3382_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","volume":"15","author":"S Betschel","year":"2019","unstructured":"Betschel S, Badiou J, Binkley K, et al. The international\/Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2019;15:72.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3382_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9:132-50.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3382_CR36","unstructured":"Takeda Pharmaceuticals. KALBITOR (ecallantide) injection for subcutaneous use, Prescribing Information. 2020. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 2025 July 24."},{"key":"3382_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jaci.2011.03.006","volume":"128","author":"AL Sheffer","year":"2011","unstructured":"Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase\u00a03 studies. J Allergy Clin Immunol. 2011;128:153-159.e4.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa0905079","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363:523\u201331.","journal-title":"N Engl J Med"},{"key":"3382_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","volume":"107","author":"WR Lumry","year":"2011","unstructured":"Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin\u00a0B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107:529-537.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3382_CR40","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaip.2016.09.023","volume":"5","author":"IM Otani","year":"2017","unstructured":"Otani IM, Lumry WR, Hurwitz S, et al. Subcutaneous icatibant for the treatment of hereditary angioedema attacks: comparison of home self-administration with administration at a medical facility. J Allergy Clin Immunol Pract. 2017;5:442-7.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3382_CR41","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/cea.14206","volume":"52","author":"M Maurer","year":"2022","unstructured":"Maurer M, Aberer W, Caballero T, et al. The icatibant outcome survey: 10\u00a0years of experience with icatibant for patients with hereditary angioedema. Clin Exp Allergy. 2022;52:1048\u201358.","journal-title":"Clin Exp Allergy"},{"key":"3382_CR42","doi-asserted-by":"publisher","first-page":"e53773","DOI":"10.1371\/journal.pone.0053773","volume":"8","author":"M Maurer","year":"2013","unstructured":"Maurer M, Aberer W, Bouillet L, et al. Hereditary angioedema attacks resolve faster and are shorter after early Icatibant treatment. PLoS ONE. 2013;8:e53773.","journal-title":"PLoS ONE"},{"key":"3382_CR43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/all.12303","volume":"69","author":"W Aberer","year":"2014","unstructured":"Aberer W, Maurer M, Reshef A, et al. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy. 2014;69:305\u201314.","journal-title":"Allergy"},{"key":"3382_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1345\/aph.1R423","volume":"47","author":"SW Cole","year":"2013","unstructured":"Cole SW, Lundquist LM. Icatibant for the treatment of hereditary angioedema. Ann Pharmacother. 2013;47:49\u201355.","journal-title":"Ann Pharmacother"},{"key":"3382_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2500\/aap.2020.41.190021","volume":"41","author":"TL Simon","year":"2020","unstructured":"Simon TL, Kalina U, Laske R, Mycroft S, Widmer E, Roth NJ. Manufacturing of plasma-derived C1-inhibitor concentrate for treatment of patients with hereditary angioedema. Allergy Asthma Proc. 2020;41:99\u2013107.","journal-title":"Allergy Asthma Proc"},{"key":"3382_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12016-018-8684-1","volume":"56","author":"H Henry Li","year":"2019","unstructured":"Henry Li H, Riedl M, Kashkin J. Update on the use of C1-esterase inhibitor replacement therapy in the acute and prophylactic treatment of hereditary angioedema. Clinic Rev Allerg Immunol. 2019;56:207\u201318.","journal-title":"Clinic Rev Allerg Immunol"},{"key":"3382_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2174\/0929867328666210804085636","volume":"29","author":"E Karnaukhova","year":"2022","unstructured":"Karnaukhova E. C1-inhibitor: structure, functional diversity and therapeutic development. CMC. 2022;29:467\u201388.","journal-title":"CMC"},{"key":"3382_CR48","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jaci.2009.07.017","volume":"124","author":"TJ Craig","year":"2009","unstructured":"Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124:801\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR49","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jpeds.2012.11.030","volume":"162","author":"W Lumry","year":"2013","unstructured":"Lumry W, Manning ME, Hurewitz DS, et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr. 2013;162:1017-22.e2.","journal-title":"J Pediatr"},{"key":"3382_CR50","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1111\/j.1537-2995.2012.03590.x","volume":"52","author":"A Gr\u00f6ner","year":"2012","unstructured":"Gr\u00f6ner A, Nowak T, Sch\u00e4fer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion. 2012;52:2104\u201312.","journal-title":"Transfusion"},{"key":"3382_CR51","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaip.2014.08.014","volume":"3","author":"P Busse","year":"2015","unstructured":"Busse P, Bygum A, Edelman J, et al. Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry. J Allergy Clin Immunol Pract. 2015;3:213\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3382_CR52","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jaip.2016.04.018","volume":"4","author":"MA Riedl","year":"2016","unstructured":"Riedl MA, Bygum A, Lumry W, et al. Safety and usage of C1-inhibitor in hereditary angioedema: Berinert registry data. J Allergy Clin Immunol Pract. 2016;4:963\u201371.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3382_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.anai.2013.12.004","volume":"112","author":"MA Riedl","year":"2014","unstructured":"Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase\u00a03, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112:163-9.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3382_CR54","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaci.2010.07.021","volume":"126","author":"B Zuraw","year":"2010","unstructured":"Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126:821-7.e14.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR55","doi-asserted-by":"publisher","first-page":"456","DOI":"10.2500\/aap.2017.38.4088","volume":"38","author":"HH Li","year":"2017","unstructured":"Li HH, Reshef A, Baker JW, Harper JR, Relan A. Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks. Allergy Asthma Proc. 2017;38:456\u201361.","journal-title":"Allergy Asthma Proc"},{"key":"3382_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa2314192","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Farkas H, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. N Engl J Med. 2024;391:32\u201343.","journal-title":"N Engl J Med"},{"key":"3382_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/acem.12341","volume":"21","author":"JJ Moellman","year":"2014","unstructured":"Moellman JJ, Bernstein JA, Lindsell C, et al. A consensus parameter for the evaluation and management of angioedema in the emergency department. Acad Emerg Med. 2014;21:469\u201384.","journal-title":"Acad Emerg Med"},{"key":"3382_CR58","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","volume":"148","author":"B Zuraw","year":"2021","unstructured":"Zuraw B, Lumry WR, Johnston DT, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase\u00a03 trial. J Allergy Clin Immunol. 2021;148:164-172.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR59","first-page":"733","volume":"12","author":"S Kiani-Alikhan","year":"2024","unstructured":"Kiani-Alikhan S, Gower R, Craig T, et al. Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: the open-label extension of the APeX-2 randomized trial. J Allergy Clin Immunol: Pract. 2024;12:733-43.e10.","journal-title":"J Allergy Clin Immunol: Pract"},{"key":"3382_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.06.004","author":"H Farkas","year":"2025","unstructured":"Farkas H, Peter JG, Stobiecki M, et al. Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema: APeX-S final results. Annal Allergy, Asthma Immunol. 2025. https:\/\/doi.org\/10.1016\/j.anai.2025.06.004.","journal-title":"Annal Allergy, Asthma Immunol"},{"key":"3382_CR61","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.anai.2023.11.016","volume":"132","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Soteres D, Sublett JW, et al. Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat. Ann Allergy Asthma Immunol. 2024;132:505-511.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3382_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.07.012","author":"J Bernatoniene","year":"2025","unstructured":"Bernatoniene J, Bourgoin-Heck M, Cancian M, et al. Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to <12\u00a0years. Annal Allergy Asthma Immunol. 2025. https:\/\/doi.org\/10.1016\/j.anai.2025.07.012.","journal-title":"Annal Allergy Asthma Immunol"},{"key":"3382_CR63","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2402478","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Tachdjian R, Lumry WR, et al. Efficacy and safety of donidalorsen for hereditary angioedema. N Engl J Med. 2024;391:21\u201331.","journal-title":"N Engl J Med"},{"key":"3382_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/all.16563","author":"MA Riedl","year":"2025","unstructured":"Riedl MA, Yarlas A, Bordone L, et al. Patient-reported outcomes in the phase\u00a0III OASIS-HAE study of donidalorsen for hereditary angioedema. Allergy. 2025. https:\/\/doi.org\/10.1111\/all.16563.","journal-title":"Allergy"},{"key":"3382_CR65","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/all.15948","volume":"79","author":"RS Petersen","year":"2024","unstructured":"Petersen RS, Bordone L, Riedl MA, et al. A phase\u00a02 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema. Allergy. 2024;79:724\u201334.","journal-title":"Allergy"},{"key":"3382_CR66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/joim.20008","volume":"296","author":"DM Cohn","year":"2024","unstructured":"Cohn DM, Renn\u00e9 T. Targeting factor\u00a0XIIa for therapeutic interference with hereditary angioedema. J Intern Med. 2024;296:311\u201326.","journal-title":"J Intern Med"},{"key":"3382_CR67","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","volume":"401","author":"TJ Craig","year":"2023","unstructured":"Craig TJ, Reshef A, Li HH, et al. Efficacy and safety of garadacimab, a factor\u00a0XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2023;401:1079\u201390.","journal-title":"Lancet"},{"key":"3382_CR68","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0805538","volume":"363","author":"BL Zuraw","year":"2010","unstructured":"Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513\u201322.","journal-title":"N Engl J Med"},{"key":"3382_CR69","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0165-2478(03)00029-4","volume":"86","author":"E Pappalardo","year":"2003","unstructured":"Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with danazol. Immunol Lett. 2003;86:271\u20136.","journal-title":"Immunol Lett"},{"key":"3382_CR70","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/trf.13462","volume":"56","author":"J Greve","year":"2016","unstructured":"Greve J, Hahn J, Nordmann M, et al. Nanofiltrated C1-esterase-inhibitor in the prophylactic treatment of bradykinin-mediated angioedema. Transfusion. 2016;56:1022\u20139.","journal-title":"Transfusion"},{"key":"3382_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013403.pub2","author":"N Beard","year":"2022","unstructured":"Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev. 2022. https:\/\/doi.org\/10.1002\/14651858.CD013403.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"3382_CR72","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/11208390-000000000-00000","volume":"25","author":"KA Lyseng-Williamson","year":"2011","unstructured":"Lyseng-Williamson KA. Nanofiltered human C1 inhibitor concentrate (Cinryze\u00ae). in hereditary angioedema. BioDrugs. 2011;25:317\u201327.","journal-title":"BioDrugs"},{"key":"3382_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01658-4","author":"WR Lumry","year":"2021","unstructured":"Lumry WR, Zuraw B, Cicardi M, et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet J Rare Dis. 2021. https:\/\/doi.org\/10.1186\/s13023-020-01658-4.","journal-title":"Orphanet J Rare Dis"},{"key":"3382_CR74","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2500\/aap.2022.43.220016","volume":"43","author":"T Craig","year":"2022","unstructured":"Craig T, Feuersenger H, Pragst I, Dang J. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema. Allergy Asthma Proc. 2022;43:202\u20138.","journal-title":"Allergy Asthma Proc"},{"key":"3382_CR75","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","volume":"376","author":"H Longhurst","year":"2017","unstructured":"Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376:1131\u201340.","journal-title":"N Engl J Med"},{"key":"3382_CR76","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/1744666X.2020.1750953","volume":"16","author":"MF Villavicencio","year":"2020","unstructured":"Villavicencio MF, Craig T. A focus on the use of subcutaneous C1-inhibitor for treatment of hereditary angioedema. Expert Rev Clin Immunol. 2020;16:451\u20135.","journal-title":"Expert Rev Clin Immunol"},{"key":"3382_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/14740338.2023.2177269","volume":"22","author":"A Yeich","year":"2023","unstructured":"Yeich A, Elhatw A, Ashoor Z, Park K, Craig T. Safety of medications for hereditary angioedema during pregnancy and lactation. Expert Opin Drug Saf. 2023;22:17\u201324.","journal-title":"Expert Opin Drug Saf"},{"key":"3382_CR78","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320:2108.","journal-title":"JAMA"},{"key":"3382_CR79","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/all.15011","volume":"77","author":"A Banerji","year":"2022","unstructured":"Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy. 2022;77:979\u201390.","journal-title":"Allergy"},{"key":"3382_CR80","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.clinthera.2008.12.021","volume":"30","author":"RS Birjmohun","year":"2008","unstructured":"Birjmohun RS, Kees Hovingh G, Stroes ESG, et al. Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema. Clin Ther. 2008;30:2314\u201323.","journal-title":"Clin Ther"},{"key":"3382_CR81","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jaci.2007.10.048","volume":"121","author":"C Drouet","year":"2008","unstructured":"Drouet C, D\u00e9sormeaux A, Robillard J, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121:429\u201333.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR82","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.anai.2015.01.003","volume":"114","author":"MA Riedl","year":"2015","unstructured":"Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol. 2015;114:281-288.e7.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3382_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110542","volume":"279","author":"HR Horv\u00e1th","year":"2025","unstructured":"Horv\u00e1th HR, Visy B, K\u0151halmi KV, et al. A national survey of four decades of hereditary angioedema prophylaxis: efficacy and safety of old and new drugs. Clin Immunol. 2025;279:110542.","journal-title":"Clin Immunol"},{"key":"3382_CR84","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa2309149","volume":"390","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst HJ, Lindsay K, Petersen RS, et al. CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema. N Engl J Med. 2024;390:432\u201341.","journal-title":"N Engl J Med"},{"key":"3382_CR85","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1056\/NEJMoa2405734","volume":"392","author":"DM Cohn","year":"2025","unstructured":"Cohn DM, Gurugama P, Magerl M, et al. Crispr-based therapy for hereditary angioedema. N Engl J Med. 2025;392:458\u201367.","journal-title":"N Engl J Med"},{"key":"3382_CR86","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.anai.2025.03.016","volume":"135","author":"W Lumry","year":"2025","unstructured":"Lumry W, Gunsior M, Cohen T, et al. Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults. Ann Allergy Asthma Immunol. 2025;135:103-111.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3382_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.419","volume":"151","author":"M Maurer","year":"2023","unstructured":"Maurer M, Anderson J, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. Efficacy and safety of bradykinin\u00a0B2 receptor inhibition with oral PHVS416 in treating hereditary angioedema attacks: results of RAPIDe-1 phase\u00a02 trial. J Allergy Clin Immunol. 2023;151:AB134.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR88","first-page":"S34","volume":"133","author":"H Wedner","year":"2024","unstructured":"Wedner H, Anderson J, Chapdelaine H, et al. Chapter-1 phase\u00a02 trial of oral bradykinin\u00a0B2 receptor antagonist deucrictibant for hereditary angioedema prophylaxis. Ann Allergy Asthma Immunol. 2024;133:S34.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3382_CR89","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaci.2023.09.039","volume":"153","author":"D Honda","year":"2024","unstructured":"Honda D, Li PH, Jindal AK, et al. Uncovering the true burden of hereditary angioedema due to C1-inhibitor deficiency: a focus on the Asia-Pacific region. J Allergy Clin Immunol. 2024;153:42\u201354.","journal-title":"J Allergy Clin Immunol"},{"key":"3382_CR90","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-021-08854-5","volume":"61","author":"AK Jindal","year":"2021","unstructured":"Jindal AK, Reshef A, Longhurst H, et al. Mitigating disparity in health-care resources between countries for management of hereditary angioedema. Clin Rev Allergy Immunol. 2021;61:84\u201397.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3382_CR91","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/14712598.2020.1724280","volume":"20","author":"H Longhurst","year":"2020","unstructured":"Longhurst H, Farkas H. Biological therapy in hereditary angioedema: transformation of a rare disease. Expert Opin Biol Ther. 2020;20:493\u2013501.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03382-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:05:11Z","timestamp":1763136311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03382-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":91,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3382"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03382-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kelsey Uminski has received educational grants from CSL Behring,\u00a0Roche and Novo Nordisk, research funding from Bayer and Novo Nordisk, consultancy fees from Bayer, Biocryst Pharmaceuticals, Novo Nordisk, Roche, Sanofi and Takeda, speaker fees from Bayer,\u00a0CSL Behring, Pfizer, Roche, Sanofi,\u00a0and Takeda, and travel support from Novo Nordisk, Octapharma, Roche,and Sanofi. Dawn Goodyear reports advisory boards and consultancy from Alexion, BioCryst, CSL Behring, Medison, Pfizer, Octapharma, Sanofi, Sobi, Roche and Takeda; research funding from Takeda. Stephen Betschel has participated in advisory board or equivalent for Astria, Biocryst Pharmaceuticals, CSL Behring, Ionis, Kalvista, Pharvaris, Sanofi and Takeda, received grants or honoraria from Biocryst Pharmaceuticals, CSL Behring, Kalvista and Takeda, and participating or participated in a clinical trial with Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}